21
Participants
Start Date
January 31, 2012
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
CD34 selected T-cell depleted allogeneic SCT
Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
New York Medical College, Valhalla
Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee
Washington University/St. Louis Children's Hospital, St Louis
University of California Los Angeles (UCLA), Los Angeles
Children's Hospital and Research Center Oakland, Oakland
Lurie Children's Hospital, Chicago
Lead Sponsor
Collaborators (1)
UCSF Benioff Children's Hospital Oakland
OTHER
Medical College of Wisconsin
OTHER
Washington University School of Medicine
OTHER
Tufts Medical Center
OTHER
University of California, San Francisco
OTHER
University of California, Los Angeles
OTHER
Miltenyi Biomedicine GmbH
INDUSTRY
Ann & Robert H Lurie Children's Hospital of Chicago
OTHER
New York Medical College
OTHER